Revolution Medicines, Inc. provided earnings guidance for the year ended December 31, 2021. The company continued to expect that its net loss for the year ended December 31, 2021 to be between $170 million and $190 million, which includes estimated non-cash stock-based compensation expense of approximately $20 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
39.06 USD | +4.06% |
|
+0.17% | +35.56% |
01:12pm | Jefferies Initiates Revolution Medicines at Buy With $63 Price Target | MT |
06-20 | Revolution Medicines Insider Sold Shares Worth $446,770, According to a Recent SEC Filing | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+35.56% | 6.19B | |
+17.35% | 45.34B | |
+42.10% | 40.42B | |
-10.39% | 37.92B | |
+32.53% | 31.75B | |
-8.98% | 27.71B | |
+12.58% | 26.52B | |
+44.01% | 13.96B | |
+31.14% | 12.44B | |
-7.30% | 11.26B |
- Stock Market
- Equities
- RVMD Stock
- News Revolution Medicines, Inc.
- Revolution Medicines, Inc. Provides Earnings Guidance for the Year Ended December 31, 2021